| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We examined clinical isolates of Neisseria gonorrhoeae for antimicrobial susceptibility and Mycoplasma genitalium DNAs for macrolide and quinolone resistance-associated mutations. We observed some isolates with decreased susceptibility to cefixime, with resistance to levofloxacin, and with resistance to azithromycin. We isolated a strain (GU140106) with decreased to ceftriaxone in 2014 but found that all other isolates were susceptible to ceftriaxone. We detected macrolide resistance-associated and/or quinolone resistance-associated mutations in M. genitalium DNAs. The presence of M. genitalium DNAs harboring both mutations suggested that some strains of M. genitalium might be evolving into multi-drug resistant ones. We should continue to pay attention to the antimicrobial susceptibility of these pathogens.
|
